pharmaphorum Podcast
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
Episodes
![Creating healthier futures - Reuters Pharma Barcelona 2023](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-84a-1400x1400_300x300.jpg)
Tuesday May 02, 2023
Tuesday May 02, 2023
In this latest mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Tommy Bramley, SVP of global consulting at Amerisource Bergen, whilst attending Reuters Pharma Barcelona.
![Inside the new world of healthcare data](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-84-1400x1400_300x300.jpg)
Thursday Apr 20, 2023
Thursday Apr 20, 2023
On today’s pharmaphorum podcast, Evidation’s Executive Chair of the Board Deborah Kilpatrick joins host Jonah Comstock to talk about healthcare data collection in 2023 and how it intersects with stakeholders across the ecosystem, from tech and pharma companies to research participants.
![Restoring sensitivity to targeted therapies](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-83a-1400x1400_300x300.jpg)
Friday Apr 14, 2023
Friday Apr 14, 2023
In this new episode of the mini pharmaphorum podcast, web editor Nicole Raleigh spoke with Simon Powell, CEO of Ribonexus, a new company put together to develop and ultimately commercialise long-standing research programmes from Gustav Roussy, Institut Curie, the University of Strasbourg, and Pierre Fabre, to develop drugs that overcome tumour resistance to existing drug treatments.
![Insulin costs & pharma manufacturing](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-83-1400x1400-NEW_300x300.jpg)
Thursday Apr 13, 2023
Thursday Apr 13, 2023
In today’s pharmaphorum podcast, brought to you by Lannett Corporation, editor in chief Jonah Comstock first chats with Timothy Crew, CEO of Lannett. Crew talks about the contract development manufacturing organisation (CDMO) business and why local manufacturing is important in the United States.
Then, in part 2, Jonah talks to Tom Lewis, Lannett’s VP of Global Supply Chain and CDMO Management. They discuss Lannett’s CDMO business more broadly, how it works, and why it’s an important offering in today’s pharma landscape.
![What the low impact of Humira biosimilars teaches us about drug prices](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-82-1400x1400_300x300.jpg)
Thursday Apr 06, 2023
Thursday Apr 06, 2023
Almost everyone seems to agree that drug prices are too high. But that agreement stops when it comes to the question of why they’re so high, and to the question of how to bring them down.
Goodroot CEO Mike Waterbury and Nuwae Health CEO Ralph Pisano discuss how the community of Goodroot companies, including Nuwae, are attacking that issue from different angles.
![Transforming healthcare: Nils Bottler and Paul Tunnah](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-00-MAR2023-1400x1400_300x300.jpg)
Thursday Mar 30, 2023
Thursday Mar 30, 2023
Angelini Ventures is a recently launched investment fund seeking companies that are transformational in healthcare. Founder of pharmaphorum and Healthware Group's chief content officer, Paul Tunnah, talks with Nils Bottler, who recently joined Angelini Ventures as Principal, about his career and where Angelini Ventures aims to have an impact.
![Challenges and opportunities with plasma-derived therapies](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-81-1400x1400_300x300.jpg)
Thursday Mar 23, 2023
Thursday Mar 23, 2023
For the newest pharmaphorum podcast, editor in chief Jonah Comstock welcomes Dr. Kristina Allikmets, SVP and head of R&D at Takeda’s plasma-derived therapies business unit.
![CinCor Pharma: A small pharma’s journey to acquisition](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-80-1400x1400_300x300.jpg)
Friday Mar 10, 2023
Friday Mar 10, 2023
In this episode of the pharmaphorum podcast, host Jonah Comstock welcomes Marc de Garidel, CEO of CinCor Pharma, which was just recently sold to AstraZeneca for more than $1 billion USD. Marc tells Jonah all about CinCor and its unique approach to hypertension, how the AstraZeneca deal came about, and what happens next.
![AI trends in 2023](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-79-1400x1400_300x300.jpg)
Thursday Mar 02, 2023
Thursday Mar 02, 2023
No matter what industry you’re in, artificial intelligence is a major topic around the water cooler. But while AI in popular culture may be at a peak of hype, AI in pharma is strending toward a moment of maturity, reliability, and scalability.
In today’s pharmaphorum podcast, brought to you by Syneos Health, Leigh Householder, EVP and MD technology and data solutions at Syneos Health and Noolie Gregory, VP decentralised clinical trial operations at Syneos Health, join host Jonah Comstock to talk about the Syneos Health 2023 Health Trends Report, particularly the opening section on AI: Finally Fit for Purpose.
![Accelerating digital healthcare, with VITA](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9188274/pharmaphorum_podcast-Episode-78-1400x1400_300x300.jpg)
Wednesday Mar 01, 2023
Wednesday Mar 01, 2023
At the beginning of February, pharmaphorum web editor Nicole Raleigh travelled to Rome to cover the inaugural VITA Accelerator demo day. After the event, VITA’s senior programme manager Anastasiya Markvarde and managing director Paolo Borella took time to discuss the ethos behind the accelerator and the future of digital health start-ups in Italy and beyond.